Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David C Linch

Showing results (11-20 of 129) with videos related to

Pageof 13
Sort By:
Hematology (Amsterdam, Netherlands)|May 15, 2003
Neutrophil elastase mutations in congenital neutropeniaPhil J Ancliff, Rosemary E Gale, David C Linch
Anti-Cancer Drugs|April 25, 2003
Debate on the conservative and aggressive treatment options for the optimal management of indolent non-Hodgkin's lymphomaKevin R Imrie, David C Linch, Myron S Czuczman
British Journal of Haematology|February 19, 2009
The production of JAK2 wild-type platelets is not downregulated in patients with JAK2 V617F mutant-positive essential thrombocythaemiaJonathan R Lambert, Rosemary E Gale, David C Linch
British Journal of Haematology|September 8, 2006
Gö6976 is a potent inhibitor of the JAK 2 and FLT3 tyrosine kinases with significant activity in primary acute myeloid leukaemia cellsVictoria L Grandage, Tamara Everington, David C Linch, et al.
Oncogene|March 1, 2005
Constitutive activation of the Wnt/beta-catenin signalling pathway in acute myeloid leukaemiaMaria Simon, Victoria L Grandage, David C Linch, et al.
Blood|April 9, 2004
Lack of effect of the human GM-CSF analog E21R on the survival of primary human acute myeloid leukemia cellsIra Jakupovic, Victoria L Grandage, David C Linch, et al.
British Journal of Haematology|October 31, 2002
Influence of cell cycling and cell division on transendothelial migration of CD34+ cellsKwee L Yong, Anne Fahey, Arnold Pizzey, et al.
Blood|August 21, 2014
X chromosome inactivation analysis reveals a difference in the biology of ET patients with JAK2 and CALR mutationsChristopher Allen, Jonathan R Lambert, David C Linch, et al.
Blood|June 23, 2009
In essential thrombocythemia, multiple JAK2-V617F clones are present in most mutant-positive patients: a new disease paradigmJonathan R Lambert, Tamara Everington, David C Linch, et al.
British Journal of Haematology|February 1, 2020
The clinical impact of mutant DNMT3A R882 variant allele frequency in acute myeloid leukaemiaDavid C Linch, Robert K Hills, Alan K Burnett, et al.
Pageof 13

Showing results (11-20 of 129) with videos related to

Sort By:
Pageof 13
Hematology (Amsterdam, Netherlands)|May 15, 2003
Neutrophil elastase mutations in congenital neutropeniaPhil J Ancliff, Rosemary E Gale, David C Linch
Anti-Cancer Drugs|April 25, 2003
Debate on the conservative and aggressive treatment options for the optimal management of indolent non-Hodgkin's lymphomaKevin R Imrie, David C Linch, Myron S Czuczman
British Journal of Haematology|February 19, 2009
The production of JAK2 wild-type platelets is not downregulated in patients with JAK2 V617F mutant-positive essential thrombocythaemiaJonathan R Lambert, Rosemary E Gale, David C Linch
British Journal of Haematology|September 8, 2006
Gö6976 is a potent inhibitor of the JAK 2 and FLT3 tyrosine kinases with significant activity in primary acute myeloid leukaemia cellsVictoria L Grandage, Tamara Everington, David C Linch, et al.
Oncogene|March 1, 2005
Constitutive activation of the Wnt/beta-catenin signalling pathway in acute myeloid leukaemiaMaria Simon, Victoria L Grandage, David C Linch, et al.
Blood|April 9, 2004
Lack of effect of the human GM-CSF analog E21R on the survival of primary human acute myeloid leukemia cellsIra Jakupovic, Victoria L Grandage, David C Linch, et al.
British Journal of Haematology|October 31, 2002
Influence of cell cycling and cell division on transendothelial migration of CD34+ cellsKwee L Yong, Anne Fahey, Arnold Pizzey, et al.
Blood|August 21, 2014
X chromosome inactivation analysis reveals a difference in the biology of ET patients with JAK2 and CALR mutationsChristopher Allen, Jonathan R Lambert, David C Linch, et al.
Blood|June 23, 2009
In essential thrombocythemia, multiple JAK2-V617F clones are present in most mutant-positive patients: a new disease paradigmJonathan R Lambert, Tamara Everington, David C Linch, et al.
British Journal of Haematology|February 1, 2020
The clinical impact of mutant DNMT3A R882 variant allele frequency in acute myeloid leukaemiaDavid C Linch, Robert K Hills, Alan K Burnett, et al.
Pageof 13